Publication:
Hypersexuality in menopausal women using serotonin reuptake inhibitors

dc.contributor.coauthorFernandez Ibanez, M.
dc.contributor.coauthorFernandez Ibanez, R.
dc.contributor.coauthorDominguez Bali, A.
dc.contributor.coauthorDominguez Bali, C.
dc.contributor.coauthorMañas, I.
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorÇakar, Aysu
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2026-07-19T19:49:31Z
dc.date.issued2026
dc.description.abstractIntroduction Hypersexuality associated with SSRI use in postmenopausal women is a rarely documented phenomenon. Only one case had been reported in the literature prior to our findings. Objective The objective is to explore the association between the use of fluoxetine and bupropion in menopausal women and the onset of hypersexual behaviors. Methods This study involved the analysis of two clinical cases concerning postmenopausal patients treated with a combination of fluoxetine (125 mg/day) and bupropion (150 mg BID) for depression. Results In the first case, a 56-year-old patient developed uncontrollable sexual behavior, engaging with multiple partners, which led to marital separation. Her compulsive behavior began one week after fluoxetine was added to her ongoing bupropion regimen. In the second case, a 58-year-old woman exhibited similar hypersexual behavior following the same fluoxetine and bupropion combination, resulting in divorce after her partner discovered the behavior. Both cases, referred by different psychiatrists, experienced full symptom resolution upon discontinuation of the medications. Conclusions These cases suggest a potential association between SSRI use (specifically the combination of fluoxetine and bupropion) and hypersexual behavior in menopausal women. It is essential to consider even rare adverse effects of these medications. Psychiatrists should remain alert to the possibility that depressive symptoms emerging during perimenopause may stem from hypoestrogenism, and therefore, hormone replacement therapy might be more appropriate than antidepressant treatment. Disclosure No
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuN/A
dc.description.versionPublished Version
dc.identifier.ScopusPercentile65
dc.identifier.ScopusQuartileQ2
dc.identifier.WoSPercentile79.5
dc.identifier.WoSQuartileQ1
dc.identifier.doi10.1093/jsxmed/qdag118.043
dc.identifier.eissn1743-6109
dc.identifier.embargoN/A
dc.identifier.issn1743-6095
dc.identifier.issue4
dc.identifier.urihttp://doi.org/10.1093/jsxmed/qdag118.043
dc.identifier.urihttps://hdl.handle.net/20.500.14288/33605
dc.identifier.volume23
dc.identifier.wos001796428200025
dc.keywordsBupropion
dc.keywordsFluoxetine
dc.keywordsDiscontinuation
dc.keywordsHypersexuality
dc.keywordsAntidepressant
dc.keywordsAdverse effect
dc.keywordsSexual dysfunction
dc.keywordsSerotonin reuptake inhibitor
dc.languageeng
dc.publisherOxford University Press
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofThe Journal of Sexual Medicine
dc.relation.openaccessN/A
dc.rightsN/A
dc.rights.uriN/A
dc.subjectUrology
dc.subjectNephrology
dc.titleHypersexuality in menopausal women using serotonin reuptake inhibitors
dc.typeMeeting Abstract
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files